Table 5 Relative CASR, RXRA, LXRA, and ENHO transcript amounts and their correlations in HD patients
Gene | Relative transcript amount Median (min-max) | A p-value for a univariate regression model, P-value for a multivariate regression model including RRT duration, dry body mass, and serum albumin concentration | ||
|---|---|---|---|---|
RXRA | LXRA | ENHO | ||
All tested HD patients (n = 112) | ||||
CASR | 0.320 (0.041–7.796) | 0.001; 0.001 | 0.015; 0.0009 | 0.087; 0.055 |
RXRA | 0.850 (0.095–2.813) | 0.018; 1.4E-5 | 2.2E-9; 2.6E-8 | |
LXRA | 1.014 (0.012–7.117) | 0.688; 0.246 | ||
ENHO | 0.666 (0.030–2.524) | |||
Patients not receiving lipid-lowering treatment (n = 77) | ||||
CASR | 0.315 (0.041–7.796) | 0.002; 0.003 | 0.040; 0.003 | 0.083; 0.044 |
RXRA | 0.875 (0.095–2.813) | 0.029; 2.2E-5 | 7.8E-6; 2.8E-5 | |
LXRA | 0.968 (0.012–7.117) | 0.902; 0.257 | ||
ENHO | 0.752 (0.030–2.466) | |||
Patients receiving lipid-lowering treatment (n = 35) | ||||
CASR | 0.395 (0.065–4.050) | 0.857; 0.987 | 0.341; 0.221 | 0.884; 0.890 |
RXRA | 0.751 (0.162–1.590) | 0.613; 0.278 | 3E-5; 7.3E-5 | |
LXRA | 1.074 (0.071–1.977) | 0.381; 0.827 | ||
ENHO | 0.531 (0.055–2.524) | |||